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Endovascular treatment with angioplasty or stenting versus 
endarterectomy in patients with carotid artery stenosis in 
the Carotid And Vertebral Artery Transluminal Angioplasty 
Study (CAVATAS): long-term follow-up of a randomised trial
Jörg Ederle, Leo H Bonati, Joanna Dobson, Roland L Featherstone, Peter A Gaines, Jonathan D Beard, Graham S Venables, Hugh S Markus, 
Andrew Clifton, Peter Sandercock, Martin M Brown, on behalf of the CAVATAS Investigators*
Summary
Background Endovascular treatment (angioplasty with or without stenting) is an alternative to carotid endarterectomy 
for carotid artery stenosis but there are scarce long-term eﬃ  cacy data showing that it prevents stroke. We therefore 
report the long-term results of the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS). 
Methods Between March, 1992, and July, 1997, patients who presented at a participating centre with a conﬁ rmed 
stenosis of the internal carotid artery that was deemed equally suitable for either carotid endarterectomy or 
endovascular treatment were randomly assigned to either treatment in equal proportions by telephone or fax from the 
randomisation service at the Oxford Clinical Trials Unit, UK. Patients were seen by an independent neurologist at 
1 and 6 months after treatment and then every year after randomisation for as long as possible, up to a maximum of 
11 years. Major outcome events were transient ischaemic attack, non-disabling, disabling, and fatal stroke, myocardial 
infarction, and death from any other cause. Outcomes were adjudicated on by investigators who were masked to 
treatment. Analysis was by intention to treat. This study is registered, number ISRCTN 01425573.
Findings 504 patients with stenosis of the carotid artery (90% symptomatic) were randomly assigned to endovascular 
treatment (n=251) or surgery (n=253). Within 30 days of treatment, there were more minor strokes that lasted less 
than 7 days in the endovascular group (8 vs 1) but the number of other strokes in any territory or death was the same 
(25 vs 25). There were more cranial nerve palsies (22 vs 0) in the endarterectomy group than in the endovascular 
group. Median length of follow up in both groups was 5 years (IQR 2–6). By comparing endovascular treatment with 
endarterectomy after the 30-day post-treatment period, the 8-year incidence and hazard ratio (HR) at the end of 
follow-up for ipsilateral non-perioperative stroke was 11·3% versus 8·6% (HR 1·22, 95% CI 0·59–2·54); for ipsilateral 
non-perioperative stroke or TIA was 19·3% versus 17·2% (1·29, 0·78–2·14); and for any non-perioperative stroke was 
21·1% versus 15·4% (1·66, 0·99 –2·80). 
Interpretation More patients had stroke during follow-up in the endovascular group than in the surgical group, but 
the rate of ipsilateral non-perioperative stroke was low in both groups and none of the diﬀ erences in the stroke 
outcome measures was signiﬁ cant. However, the study was underpowered and the conﬁ dence intervals were wide. 
More long-term data are needed from the on going stenting versus endarterectomy trials.
Funding British Heart Foundation; UK National Health Service Management Executive; UK Stroke Association.
Introduction
Carotid endarterectomy became the mainstay of 
treatment for patients with symptomatic carotid artery 
stenosis after two randomised trials established the 
beneﬁ t of endarterectomy compared with medical 
treatment.1,2 In recent years, endovascular treatments 
(ﬁ rst balloon angioplasty and then stenting) have been 
increasingly used as an alternative to endarterectomy, 
despite the paucity of evidence that endovascular 
treatment oﬀ ers the same level of early safety and 
long-term eﬀ ectiveness as surgery does. Several 
randomised trials have compared endovascular treatment 
with endarterectomy for carotid stenosis, but none have 
been of suﬃ  cient duration to report outcome after longer 
than 4 years.3
The Carotid and Vertebral Artery Transluminal 
Angioplasty Study (CAVATAS) is a randomised controlled 
trial to assess the safety and eﬃ  cacy of endovascular 
treatment compared with endarterectomy for carotid 
stenosis. CAVATAS comprises three international 
multicentre randomised controlled trials, which started 
randomisation in 1992. CAVATAS-MED compared 
endovascular with medical treatment of carotid stenosis 
in patients who were not suitable for surgery; only a 
small number of patients were randomly assigned in this 
trial.4 CAVATAS-VER compared endovascular with 
medical treatment for symptomatic vertebral artery 
stenosis, and the long-term results were published in 
2007.5 CAVATAS compared endovascular treatment 
(angioplasty with or without stenting) with surgery in 
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patients with mainly symptomatic carotid artery stenosis, 
and the long-term results are reported here. We published 
the ﬁ rst report from CAVATAS—the safety outcome after 
30 days of treatment with a maximum follow-up of 
3 years—in 2001.6 Since then, two other multicentre 
randomised controlled trials that have compared carotid 
stenting with endarterectomy in patients with 
symptomatic carotid artery stenosis have published safety 
data and medium-term follow-up data, namely the Stent 
Protected Angioplasty versus Carotid Endarterectomy 
trial (SPACE), which had a follow-up period of 2 years, 
and the Endarterectomy versus Angioplasty in patients 
with Symptomatic Severe Carotid Stenosis trial (EVA-3S), 
which had a follow-up of 4 years.7,8 However, the long-term 
eﬃ  cacy of endovascular treatment compared with surgery 
after the ﬁ rst few years has not been published. We 
therefore report the ﬁ nal results of CAVATAS, including 
long-term data up to a maximum of 11 years’ follow-up 
with the aim of assessing the long-term eﬀ ectiveness of 
angioplasty and stenting compared with surgery in 
patients with symptomatic carotid artery stenosis.
Methods
Patients
The inclusion criteria for CAVATAS have been described 
previously.6 In brief, between March, 1992, and July, 1997, 
patients that were referred to the 22 trial centres in western 
Europe, Australia, or Canada with stenosis of the internal 
carotid artery that was deemed by the investigators to 
require treatment and was equally suitable for carotid 
endarterectomy or endovascular treatment were included 
in CAVATAS. Exclusion criteria included unwillingness to 
undergo one of the procedures, inability to give informed 
consent, and disabling stroke within the region supplied 
by the treated artery without useful recovery of function. 
There was no upper age limit for participation in the study. 
All patients provided written informed consent and each 
centre obtained local ethics committee approval.
Randomisation and masking
Patients were randomly assigned in equal proportions 
to endovascular treatment or endarterectomy in 
response to a telephone call or fax to the randomisation 
service at the Oxford Clinical Trials Unit, UK. Follow-up 
examinations were done by investigators who were 
neurologically trained but were not directly involved in 
the endovascular treatment or endarterectomy. All 
strokes and deaths were adjudicated masked to 
treatment allocation and based on the information 
provided by the individual centres, including brain 
scans and, where appropriate, death certiﬁ cates.
Procedures
Participating centres used their own protocol to establish 
the presence of carotid stenosis, but in most cases 
ultrasound ﬁ ndings were conﬁ rmed by catheter 
angiography.
All patients enrolled before 1994 who received endo-
vascular treatment had percutaneous balloon angioplasty. 
Stents suitable for the carotid artery became available 
during the course of the study. From 1994, stenting was 
allowed at the discretion of the intervening radiologist. 
Patients were seen for follow-up at 1 and 6 months after 
treatment, and then every year after randomisation by an 
independent neurologist or stroke physician. There was 
no pre-determined total length of follow-up, but 
investigators were encouraged to continue follow-up for 
as long as they and their patients were willing to do so.
Outcome events reported to the central oﬃ  ce were 
transient ischaemic attack (TIA), non-disabling, disabling, 
and fatal stroke, myocardial infarction, and death from 
any other cause. Amaurosis fugax was included in the 
category of TIA. Mortality and certiﬁ ed cause of death was 
conﬁ rmed from the General Register Oﬃ  ce (GRO) in 
patients randomly assigned at UK centres. Stroke was 
deﬁ ned as a clinical syndrome of acute onset of a focal 
neurological deﬁ cit that lasted longer than 24 h, was of 
vascular origin, and was classiﬁ ed as disabling if the 
patient required help from another person for more than 
30 days as a result of the stroke. Stroke was classiﬁ ed as 
fatal if death was deemed to be a direct result of the stroke 
at any time after onset. Other stroke events were classiﬁ ed 
as non-disabling; non-disabling strokes were divided into 
those that lasted fewer than 7 days and those that lasted 
more than 7 days, to enable comparison with the European 
Carotid Surgery Trial (ECST), which only reported strokes 
that lasted more than 7 days.1 TIA was deﬁ ned as an acute 
disturbance of focal neurological function with symptoms 
that lasted less than 24 h and was attributable to 
cerebrovascular disease. Death was classiﬁ ed as other 
vascular death if it was due to any cardiovascular-related 
252 randomly assigned to 
endovascular treatment 
253 randomly assigned to 
endarterectomy
1 with carotid occlusion excluded
240 received endovascular treatment
3 died before treatment
1 had stroke before treatment
6 crossed over to endarterectomy
1 received only medical care 
246 received endarterectomy
1 died before treatment
1 had stroke before treatment
2 crossed over to endovascular 
treatment
3 received only medical care 
251 followed-up and analysed 
(intention-to-treat population)
253 followed-up and analysed
(intention-to-treat population) 
505 patients randomised
Figure 1: Trial proﬁ le
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illness other than stroke (including myocardial infarction 
and pulmonary embolism). Death caused by any other 
non-vascular-related illness was classiﬁ ed as non-vascular. 
If no information on the cause of death was available, the 
cause was classiﬁ ed as undetermined. Outcome events 
were classiﬁ ed as perioperative if they occurred at the 
time of treatment or within 30 days after treatment. In 
patients who did not have an intervention, the date of 
crossover to medical treatment was deﬁ ned as the 
proxy-treatment date for the purpose of analysing the rate 
of events that occurred more than 30 days after treatment, 
which were deﬁ ned as non-perioperative events.
The original study protocol deﬁ ned the primary 
outcome measure as long-term period free from disabling 
stroke or death from the time of randomisation as an 
outcome that was relevant to the patient and health 
economics. In this paper, to assess the long-term eﬃ  cacy 
of treatment to prevent stroke after treatment we 
compared the occurrence of non-perioperative TIA, 
stroke, or both, in various territories, excluding 
perioperative events that occurred within 30 days after 
treatment. Additionally, we assessed whether the use of 
stenting versus only balloon angioplasty and whether the 
baseline characteristics, including age dichotomised at 
the median age, inﬂ uenced the rates of strokes that lasted 
more than 7 days or perioperative death. For each outcome 
measure, patients were counted only once; the ﬁ rst event 
was the event of interest, whenever this occurred. 
However, patients who had more than one outcome event 
were counted in each relevant outcome category.
Statistical analysis
All data were analysed by intention-to-treat with SPSS 
version 16.0 for Mac (Chicago, IL, USA) except where 
stated. The log-rank test was used to compare the survival 
experience free of events in the two treatment groups. A 
Cox proportional hazard model was used to obtain an 
estimate of the treatment eﬀ ect (hazard ratio), with 
endarterectomy used as the reference group. The 
proportional hazards assumption was checked with a 
graphical log-minus-log method. Censoring was assumed 
to be non-informative. All outcome events up to the last 
available follow-up or death of the patient were included in 
the calculation of hazard ratios. However, because fewer 
than 50 patients were followed up beyond 8 years, 
Kaplan–Meier curves were only plotted up to 8 years after 
randomisation. Cox regression was used to test for 
treatment eﬀ ect interaction within the subgroups. This 
study is registered, number ISRCTN 01425573.
Role of the funding source
The sponsors had no role in the study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
505 patients with carotid artery stenosis who were 
suitable for either endovascular treatment or carotid 
Endovascular treatment 
(n=251)
Endarterectomy 
(n=253)
Age (years) 68 (62–73) 68 (62–73)
Sex
Women 77 (31%) 75 (30%)
Men 174 (69%) 178 (70%)
Vascular risk factors
Hypertension 132 (53%) 144 (58%)
Systolic blood pressure (mm Hg) 151·8 (21·8) 152·6 (20·1)
Diastolic blood pressure (mm Hg) 83·5 (11·8) 83·9 (10·7)
Diabetes mellitus 35 (14%) 32 (13%)
Cholesterol >6·5 mmol/L 67 (34%) 62 (32%)
Smoker (past or current) 191 (77%) 192 (78%)
History of cardiovascular or cerebrovascular disease
Myocardial infarction 43 (19%) 40 (17%)
Atrial ﬁ brillation 12 (5%) 12 (5%)
Peripheral vascular disease 60 (24%) 51 (20%)
Cerebrovascular symptoms >6 months before 
randomisation
21 (8%) 15 (6%)
Treatments at randomisation
Antiplatelet 216 (86%) 230 (91%)
Warfarin 23 (10%) 28 (11%)
Cerebrovascular events within 6 months before randomisation
Transient ischaemic attack 94 (37%) 98 (39%)
Amaurosis fugax 60 (24%) 63 (25%)
    Hemisphere stroke
    Minor 19 (8%) 20 (8%)
    Major (non-disabling) 32 (13%) 28 (11%)
    Major (disabling) 11 (4%) 18 (7%)
    Retinal infarct 5 (2%) 3 (1%)
Degree of symptomatic carotid stenosis*
60–69% 15 (6%) 16 (6%)
70–79% 34 (14%) 40 (16%)
80–89% 91 (36%) 92 (36%)
90–99% 109 (43%) 98 (39%)
Contralateral carotid stenosis of 70–99% or occlusion* 78 (31%) 79 (32%)
Time from randomisation to treatment (days) 20·0 (8·0–32·0) 27·0 (13·5–41·0)
Follow-up (years) 5 (2–6) 5 (2–6)
Treatments, blood pressure, and smoking status during follow-up†
Antiplatelet 202 (92%)
43 (86%)
209 (90%)
47 (90%)
Warfarin 12 (6%)
4 (8%)
12 (5%)
2 (4%)
Systolic blood pressure (mm Hg) 151·0 (21·0)
153·9 (23·2)
151·0 (23·4)
147·6 (26·5)
Diastolic blood pressure (mm Hg) 83·0 (10·1)
78·3 (12·3)
82·7 (10·2)
77·6 (14·0)
Smoker (past or current) 48 (23%)
5 (11%)
50 (22%)
12 (27%)
Data are number (%), median (IQR), or mean (SD) unless otherwise indicated. *Measured by common carotid method. 
†The ﬁ rst line for each characteristic is taken from 1-year follow-up data and the second line from the 6-year follow-up data.
Table 1: Patient characteristics at baseline
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endarterectomy were randomly assigned to endovascular 
treatment (n=252), or endarterectomy (n=253). Figure 1 
shows the trial proﬁ le. One patient with carotid occlusion 
was randomly assigned to endovascular treatment in 
error and was excluded, leaving 504 patients for the 
analysis. 18 patients did not receive the treatment they 
were allocated to. The baseline characteristics were well 
balanced, and 90% of patients had symptoms within 
6 months before randomisation (table 1).6
Follow-up data were available for up to 11 years after 
randomisation. The median length of follow-up in both 
groups was 5 years (IQR 2–6 years). The use of 
antithrombotic medications, control of blood pressure, 
and smoking rates were well matched in the two arms 
throughout the course of the trial (table 1). Data on the 
use of statins were not collected. 
Tables 2 and 3 report the number of main outcome 
events. The rates of any stroke that lasted for more than 
7 days or death within 30 days of treatment were well 
matched between the treatment groups (10% in each 
arm). There were more minor strokes that lasted fewer 
than 7 days within 30 days of treatment in the endovascular 
group than in the endarterectomy group (8 vs 1), but there 
were more cranial nerve palsies in the endarterectomy 
group than in the endovascular group (0 vs 22). Most 
cranial nerve palsies were transient, but the symptoms 
were still present in one patient 1 month after treatment 
and had resolved by the 6-month follow-up. The primary 
outcome measure of disabling stroke or death at any time 
after randomisation was recorded in 238 patients 
(endovascular n=117, surgery n=121; table 3). The 8-year 
cumulative incidence of disabling stroke or death 
estimated from the Kaplan–Meier survival analysis was 
45·2% (SE 4·0%) in the endovascular treatment group 
Endovascular 
treatment 
(n=251)
Endarterectomy 
(n=253)
Fatal stroke 7 (3%) 1 (0·3%)
Non-stroke death 0 3 (2%)
Disabling stroke 9 (4%) 11 (4%)
Non-disabling stroke that lasted 
more than 7 days
9 (4%) 10 (4%)
Non-disabling stroke that lasted 
fewer than 7 days
8 (3%) 1 (0.3%)
Death or disabling stroke 16 (6%) 15 (6%)
Death or any stroke that lasted more 
than 7 days
25 (10%) 25 (10%)
Cranial nerve palsy* 0 22 (9 %)
Haematoma that required surgery or 
extended stay in hospital†
3 (1%) 17 (7%)
Non-fatal myocardial infarction 0 3 (1%)
Pulmonary embolus 0 2 (1%)
Data are number (%). Stroke refers to events in any territory. *p<0·0001. 
†p <0·002. Other diﬀ erences not signiﬁ cant.
Table 2: Outcome events within 30 days after ﬁ rst treatment 
Endovascular 
treatment 
(n=251)*
Endarterectomy 
(n=253)†
Disabling stroke or death 117 121
Stroke 33 27
Disabling 18 21
Fatal 15 6
Non-stroke death 84 94
Stroke that lasted >7 days or death 134 131
Stroke that lasted >7 days 59 47 
Fatal 14 6
Disabling 17 19
Non-disabling 28 22
Non-stroke death 75 84 
Perioperative 0 3
Non-perioperative 75 81
Any stroke or perioperative death 67 51
Any stroke 67 48
Fatal 14 6
Disabling 17 19
Non-disabling >7 days 28 22
Non-disabling <7 days 8 1
Perioperative death 0 3
Vascular non-stroke 0 2
Non-vascular 0 1
Non-perioperative stroke or TIA 67 51
Non-perioperative stroke 31 18 
Fatal 6 4
Disabling 7 5
Non-disabling 18 9
Non-perioperative TIA 36‡ 33§
Non-perioperative ipsilateral stroke or TIA 34 27
Non-perioperative ipsilateral stroke 12 11 
Fatal 1 1
Disabling 3 2
Non-disabling 8 8
Non-perioperative ipsilateral TIA 22¶ 16||
Non-perioperative non-ipsilateral stroke 24 13 
Fatal 8 4
Disabling 5 6
Non-disabling 11 3
Death 112 113
Stroke death 16 6
Vascular non-stroke death 43 53
Non-vascular 44 46
Undetermined 9 8
Data are number of events. None of the diﬀ erences were statistically signiﬁ cant. Indented lines below 
combined outcome measures indicate how many events contributed to the combined outcome measure. 
All non-perioperative strokes lasted for more than 7 days. TIA=transient ischaemic attack. *Total person-years 
of follow-up=1098. †Total person-years of follow-up=1083. ‡6 patients had a subsequent non-perioperative 
stroke (1 fatal, 2 disabling, 3 non-disabling). §5 patients had a subsequent non-perioperative stroke (1 fatal, 
3 disabling, 1 non-disabling). ¶4 patients had a subsequent non-perioperative ipsilateral stroke (1 disabling, 
3 non-disabling). ||2 patients had a subsequent non-perioperative ipsilateral stroke (1 disabling, 
1 non-disabling). 
Table 3: Major long-term outcome events 
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218
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58
43
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24
24
251
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23·5% (3·5)
45·2% (4·0)
50·4% (4·1)
36·9% (5·0)
30·2% (4·7)
19·3% (4·0)
17·2% (3·8)
26·6% (3·4)
23·1% (3·5)
21·1% (4·1)
15·4% (4·3)
11·3% (3·7)
8·6% (3·1)
48·4% (4·2)
43·0% (4·0)
Figure 2: Kaplan–Meier estimates of cumulative incidence
The numbers above and below the lines refer to the 8-year incidence (SE) (%). (A) Disabling stroke or death (primary outcome measure). (B) Any stroke or 
perioperative death. (C) Stroke that lasted more than 7 days or perioperative death within 30 days of treatment. (D) Non-perioperative stroke or TIA. 
(E) Non-perioperative stroke. (F) Non-perioperative ipsilateral stroke or transient ischaemic attack. (G) Non-perioperative ipsilateral stroke. (H) Any cause of death. 
Except where stated, stroke refers to events in any territory. A, B, C, and H are analysed from date of randomisation; D and G are analysed from 30 days after 
treatment. No stroke that occurred more than 30 days after treatment lasted for fewer than 7 days. 
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and  50·4% (4·1%) in the endarterectomy group (ﬁ gure 2). 
After 8 years (data not shown) the lines for each treatment 
came together and crossed, indicating an overall risk that 
was virtually identical in both groups (HR 1·02, 95% CI 
0·79–1·32; table 4). 
Any stroke or perioperative death were more frequent 
in the endovascular treatment group than they were in 
the surgery group. The estimated cumulative 8-year risk 
was 29·7% (SE 3·4%) after endovascular treatment and 
23·5% (3·5%) after surgery (ﬁ gure 2). The hazard ratio 
between the two treatments was not signiﬁ cantly diﬀ erent 
(HR 1·35, 0·94–1·93; table 4).
All the stroke outcome events recorded during follow-up 
longer than 30 days after treatment lasted more than 
7 days. Only one of these events (a non-disabling stroke 
during endovascular treatment of restenosis in the 
endovascular arm) occurred as a result of carotid 
revascularisation. The estimated 8-year cumulative 
incidence of stroke that lasted for more than 7 days or 
death after randomisation, including perioperative events, 
was 54·4% (SE 4·0%) in the endarterectomy group and 
52·9% (4·0%) in the endovascular treatment group. The 
overall risk diﬀ erence was not signiﬁ cant (HR 1·08, 
95% CI 0·85–1·38). Non-cerebrovascular death accounted 
for most of the deaths. By restricting the analysis to death 
due to perioperative events, there was no signiﬁ cant 
diﬀ erence in the estimated 8-year occurrence of stroke 
that lasted more than 7 days or perioperative death in the 
endovascular group (26·6%, SE 3·4%) compared with the 
surgery group (23·1%, 3·5%; HR 1·19, 95% CI 0·82–1·72, 
ﬁ gure 2 and table 4). The estimated 8-year cumulative 
occurrence of any cause of death was greater after carotid 
endarterectomy than it was after endovascular treatment 
(ﬁ gure 2), but the lines for each treatment came together 
and crossed after 8 years (data not shown) and the overall 
risk was not signiﬁ cantly diﬀ erent (1·07, 0·82–1·40; 
table 4).
The combined outcome of non-perioperative stroke or 
TIA was more common in the endovascular group than 
it was in the endarterectomy group, but the diﬀ erence 
was not signiﬁ cant (HR 1·37, 95% CI 0·95–1·97). The 
8-year cumulative incidence was estimated as 36·9% 
(SE 5·0%) in the endovascular group and 30·2% (4·7%) 
in the endarterectomy group (ﬁ gure 2). Non-perioperative 
stroke in any territory was also more common in the 
endovascular group than in the endarterectomy group, 
with the 8-year cumulative incidence in the endovascular 
group estimated as 21·1% (SE 4·1%) compared with 
15·4% (4·3%) in the endarterectomy group; however, the 
diﬀ erence was not signiﬁ cant (1·66, 0·99–2·80; ﬁ gure 2 
and table 4). When the analysis was restricted to ipsilateral 
events that occurred in the territory of the randomised 
vessel, the 8-year cumulative incidence of 
non-perioperative stroke or TIA was similar in the 
endovascular and surgery groups (19·3% [SE 4·0%] vs 
17·2% [3·8%]; ﬁ gure 2); the diﬀ erence was not signiﬁ cant 
(1·29, 0·78–2·14; table 4). The diﬀ erence was similar 
when the analysis was done by treatment received rather 
than by intention-to-treat (1·25, 0·76–2·06).
The estimated cumulative 8-year incidence of 
non-perioperative ipsilateral stroke was 11·3% (SE 3·7%) 
in the endovascular group and 8·6% (3·1%) in the 
endarterectomy group (ﬁ gure 2). The overall risk 
diﬀ erence was not signiﬁ cant when the data were 
analysed by intention-to-treat (1·22, 0·59–2·54; table 4) 
or by treatment received (1·10, 0·53–2·28). The 
cumulative incidence of non-perioperative stroke in a 
non-randomised vascular territory (contralateral or 
vertebrobasilar) at 8 years was also not signiﬁ cantly 
diﬀ erent (11·6% [SE 2·5%] vs 11·2% [4·2%]; 1·90, 
0·97–3·73).
23% (n=55) of the patients randomly assigned to 
endovascular treatment had stenting. The remaining 
patients were treated with balloon angioplasty only. The 
8-year cumulative occurrence of stroke that lasted for 
more than 7 days or perioperative death, analysed by 
treatment received, was 24% after balloon angioplasty, 
34% after stenting, and 21% after endarterectomy. The 
higher risk in patients who had stenting compared with 
those treated by balloon angioplasty only was not 
signiﬁ cant (1·33, 0·72–2·46). This outcome included 
patients whose stroke occurred at the time of balloon 
insertion but before the stent was deployed. Excluding 
perioperative events, the risk of ipsilateral non-
perioperative stroke was lower after stenting than it was 
after angioplasty alone, but the diﬀ erence was not 
signiﬁ cant (0·66, 0·25–1·71). 
Subgroup analysis to assess the inﬂ uence of baseline 
variables on the long-term rate of any stroke that lasted 
more than 7 days or perioperative death showed no 
signiﬁ cant interaction with treatment eﬀ ect of any of the 
variables tested (ﬁ gure 3). In patients younger than 
68 years, there was no signiﬁ cant diﬀ erence in the rate of 
stroke or perioperative death between endovascular 
treatment and endarterectomy (1·05, 0·61–1·83). 
Although the HR was higher in patients aged 68 years or 
Hazard ratio (95% CI)
Disabling stroke or death 1·02 (0·79–1·32)
Any stroke lasting > 7 days or death  1·08 (0·97–3·73)
Any stroke or perioperative death 1·35 (0·94–1·93)
Stroke lasting >7 days or perioperative death 1·19 (0·82–1·72)
Non-perioperative stroke or TIA 1·37 (0·95–1·97)
Non-perioperative stroke 1·66 (0·99–2·80)
Non-perioperative ipsilateral stroke or TIA 1·29 (0·78–2·14)
Non-perioperative ipsilateral stroke 1·22 (0·59–2·54)
Non-perioperative, non-ipsilateral stroke  1·08 (0·97–3·73)
Any cause of death 1·07 (0·82–1·40)
Data are hazard ratio (95% CI). Hazard ratios are calculated by intention-to-treat 
and are based on all available follow-up to a maximum of 11 years. TIA=transient 
ischaemic attack.
Table 4: Hazard ratios for all outcome measures
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older (1·32, 0·79 to 2·20), this was not signiﬁ cant. 
Furthermore, the HR for endovascular treatment 
compared with endarterectomy was non-signiﬁ cantly 
greater in patients with ischaemic heart disease (1·88, 
1·00–3·54).
Discussion
CAVATAS was a randomised controlled trial of 
endovascular treatment compared with endarterectomy 
for the treatment of mainly symptomatic carotid artery 
stenosis. CAVATAS was designed to provide data on two 
main questions regarding the endovascular treatment of 
atherosclerotic carotid artery stenosis. First, how safe is 
endovascular treatment compared with carotid 
endarterectomy in terms of 30-day outcome events; 
second, how do the two procedures compare in terms of 
their long-term eﬀ ectiveness in preventing post-treatment 
stroke. The initial short-term data, published in 2001, 
showed similar rates of the major complications of stroke 
lasting more than 7 days or death, within 30 days of 
treatment, but the rates in both arms were unacceptably 
high (around 10%),6 which mandated further trials to 
compare stenting with endarterectomy for symptomatic 
carotid stenosis and determine whether the safety of 
treatment could be improved. Several of these have 
published their initial ﬁ ndings of outcome events within 
30 days of the procedure.9–13 The most recent of these, 
EVA-3S and SPACE, did not establish the equivalence of 
carotid stenting with endarterectomy in terms of early 
safety. We concluded in our recent meta-analysis of all 
available randomised data that the results of the trials did 
not support a change in clinical practice away from 
recommending carotid endarterectomy as the treatment 
of choice for suitable carotid artery stenosis.3 Moreover, 
the long-term eﬃ  cacy of endovascular treatment to 
prevent stroke, which is the main aim of the treatment of 
carotid stenosis, remained unclear. 
Here, we have reported new data on the safety of the 
endovascular treatment. In the original analysis published 
in 2001,6 the steering committee prospectively decided 
that only strokes that lasted longer than 7 days would be 
included in the analysis of perioperative events occurring 
within 30 days of treatment, to match the European 
Carotid Surgery Trial (ECST), which also only reported 
strokes that lasted longer than 7 days. This criterion was 
also chosen to avoid ascertainment bias related to the 
concern that some short-lived events would be missed in 
patients who had surgery and were operated on under 
general anaesthesia and returned to surgical wards 
compared with patients who had endovascular treatment 
under local anaesthesia and were returned immediately to 
neurological wards. Our current ﬁ nding that minor 
strokes with symptoms that lasted fewer than 7 days were 
reported more frequently in the 30 days after treatment in 
the endovascular arm than in the endarterectomy arm 
(8 vs 1), whereas there was no signiﬁ cant diﬀ erence in the 
rate of stroke that lasted longer than 7 days, or death, could 
be seen as conﬁ rmation of an ascertainment bias in favour 
of the minor strokes, or could show additional hazards 
from endovascular treatment at the time. The number of 
minor strokes in the endovascular group was more than 
oﬀ set by the number of cranial nerve palsies after 
endarterectomy (8 minor strokes vs 22 cranial nerve 
palsies), one of which did not resolve until the 6 month 
follow-up. 
The ﬁ nal results of CAVATAS reported here provide the 
ﬁ rst randomised data on the long-term outcome up to 
11 years after endovascular treatment. Most events during 
follow-up (62%) were deaths, and the 5-year and 10-year 
Sex
Women 21/77 12/75 1·63 (0·80–3·33) 0·30
Men 39/174 39/178 1·04 (0·67–1·63)
Age
<68 years 27/120 24/115 1·05 (0·61–1·83) 0·56
≥68 years 33/131 27/138 1·32 (0·79–2·20)
Qualifying event
Stroke 21/62 18/66 1·23 (0·65–2·31) 0·99
TIA 28/94 24/98 1·24 (0·72–2·13)
Ocular 7/65 6/66 1·20 (0·40–3·58)
Severity of stenosis
<70%  2/15 4/22 0·64 (0·12–3·47) 0·46
≥70% 58/236 47/231 1·22 (0·83–1·79)
Contralateral stenosis
<50% 25/112 19/117 1·32 (0·72–2·39) 0·67
≥50% 35/139 32/136 1·11 (0·69–1·80)
Hypertension
No 23/117 19/106 1·10 (0·60–2·01) 0·71
Yes 37/132 32/144 1·27 (0·79–2·04)
Diabetes
No 51/211 42/215 1·24 (0·83–1·87) 0·93
Yes 9/35 7/32 1·18 (0·44–3·18)
Smoking
No 11/56 10/57 1·04 (0·44–2·45) 0·73
Yes 49/191 41/192 1·23 (0·81–1·86)
Ischaemic heart disease
No 32/152 36/157 0·88 (0·54–1·41) 0·06
Yes 27/95 15/92 1·88 (1·00–3·54)
Previous MI
No 43/187 40/193 1·07 (0·70–1·65) 0·39
Yes 12/43 7/40 1·69 (0·67–4·30)
0
Favours endovascular treatment Favours endarterectomy
1 2 3 4 5
Number of events (n/N) HR (95% CI) p value
EVT CEA
Figure 3: Subgroup analysis to compare the rates of the outcome event of stroke in any territory that lasted 
more than 7 days or perioperative death, according to various baseline characteristics
p values are associated with treatment–covariate interaction tests. The dotted vertical line is the hazard ratio in the 
overall population. Analyses are by intention to treat. n=number of events. N=number of patients in each group. 
EVT=endovascular treatment. CEA=carotid endarterectomy. HR=hazard ratio. TIA=transient ischaemic attack. 
MI=myocardial infarction.
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risks of mortality were 22% and 75%, respectively. The 
long-term rate of ipsilateral stroke was similar to that 
recorded in the endarterectomy arms of previous trials: 
ECST reported a 10-year risk of ipsilateral stroke after 
carotid endarterectomy (excluding perioperative events) 
of 9·7%,14 which is similar to the 8-year risk of 8·6% after 
surgery and 11·3% after endovascular treatment reported 
here. The comparison of the primary outcome measure 
of long-term survival free of disabling stroke or death 
(including perioperative events) in CAVATAS showed no 
diﬀ erence between endovascular treatment and 
endarterectomy (HR 1·02, 95% CI 0·79–1·32) and the 
rate after randomisation of any stroke that lasted longer 
than 7 days or perioperative death was also not 
signiﬁ cantly diﬀ erent (1·19, 0·82–1·72). There was also 
no signiﬁ cant diﬀ erence in the rate of outcome events 
between the two arms if only events occurring more than 
30 days after treatment are analysed, although there were 
more events in those patients allocated to endovascular 
treatment. EVA-3S and SPACE also found little diﬀ erence 
in the rates of ipsilateral non-perioperative stroke more 
than 30 days after treatment when patients assigned to 
carotid stenting were compared with those assigned to 
endarterectomy over a shorter length of follow-up 
(maximums of 4 and 2 years, respectively).7–8 The result of 
a meta-analysis of the data from all three trials suggested 
that both methods of treatment have similar eﬃ  cacy at 
preventing long-term ipsilateral stroke after the treatment 
period (ﬁ gure 4), but with wide conﬁ dence intervals (odds 
ratio 1·18, 95% CI 0·70–1·99). Further long-term data are 
needed from the large on going randomised stenting 
trials, to ascertain whether the small diﬀ erence in favour 
of endarterectomy becomes signiﬁ cant or not with larger 
numbers of patients and outcome events.
CAVATAS was one of the earliest clinical trials of 
endovascular treatment, and most patients in the 
endovascular treatment group were treated with just 
angioplasty. Stenting was primarily used as a secondary 
procedure when balloon angioplasty alone produced an 
unsatisfactory result. Stents were used in 55 patients 
(26%), in whom endovascular treatment was deemed 
technically successful (balloon inﬂ ation or stent 
deployment across the lesion).6 Primary stenting has 
subsequently replaced balloon angioplasty as the 
radiological technique of choice for carotid stenosis. 
Additionally, the technical equipment used in 
endovascular treatment has improved since CAVATAS. 
However, there are no data from randomised trials to 
support the notion that stenting is superior to angioplasty 
alone. The exploratory subgroup analysis of patients 
treated with stenting compared with those treated with 
only balloon angioplasty showed no signiﬁ cant diﬀ erence 
in the risk of stroke that lasted more than 7 days or 
perioperative death (1·33, 0·72–2·46), but this outcome 
included some patients whose stroke occurred as a result 
of full balloon deployment before a stent was inserted as 
a rescue procedure. The risk of ipsilateral non-
perioperative stroke was lower after stenting than after 
angioplasty alone, but the number of events was small 
and the diﬀ erence was not signiﬁ cant (0·66, 0·25–1·71).
One of the concerns about endovascular techniques is 
that angioplasty and stenting might be associated with a 
higher rate of restenosis than is endarterectomy. We 
report the results of analysis of the ultrasound follow-up 
from those centres in CAVATAS where ultrasound was 
available in a companion paper.15 The ultrasound data 
conﬁ rmed that severe restenosis (≥70%) was found 
signiﬁ cantly more commonly in patients after 
endovascular treatment than after endarterectomy, and 
the long-term risk of severe carotid restenosis or occlusion 
in CAVATAS was three times higher after endovascular 
treatment than after endarterectomy (adjusted HR 3·17, 
1·89–5·32; p<0·0001). Severe carotid restenosis or 
occlusion after endovascular treatment or endarterectomy 
was also associated with an increased risk of recurrent 
ipsilateral cerebrovascular events (adjusted HR for the 
rate of ipsilateral non-perioperative stroke or TIA 2·18, 
1·04–4·54; p=0·04) but the increase in recurrent ipsilateral 
stroke alone was not signiﬁ cant (1·67, 0·54–5·11; p=0·4). 
Several tests were done to ascertain whether risk factors 
predicted outcome, regardless of treatment allocation. 
None of these subgroup analyses showed a signiﬁ cant 
interaction between baseline variables and treatment 
eﬀ ect. In patients younger than 68 years there was no 
diﬀ erence in risk of stroke that lasted more than 7 days or 
perioperative death according to treatment allocation 
(1·05, 0·61–1·83), but the hazard ratio for endovascular 
treatment in patients aged 68 years or older was higher 
than that for endarterectomy (1·32, 0·79–2·20). Although 
little emphasis can be placed on this ﬁ nding, these results 
are consistent with the ﬁ ndings reported by the EVA-3S 
and SPACE investigators.7,8 The subgroup analyses also 
suggest that patients with ischaemic heart disease might 
have a lower long-term rate of stroke after treatment with 
endarterectomy than after treatment with endovascular 
methods.
Study or 
subgroup
Endovascular 
treatment
Events Total Events Total
Endarterectomy Weight (%) Odds ratio (Peto, 
ﬁxed, 95% CI)
0·01 0·1
Favours endovascular treatment Favours endarterectomy
1 10 100
CAVATAS–CEA 16 251 13 253 48·0 1·26 (0·59–2·67)
EVA–3S 4 265 4 262 14·0 0·99 (0·24–3·99)
SPACE 12 545 10 526 38·0 1·16 (0·50–2·71)
Total (95% CI) 32 1061 27 1041 100·0 1·18 (0·70–1·99)
Heterogeneity: χ2=0·09, df=2 (p=0·96); I2=0%
Test for overall eﬀect: Z=0·62 (p=0·54)
Figure 4: Meta-analysis of the main multicentre randomised controlled trials
Comparison of long-term beneﬁ t of endovascular treatment versus endarterectomy for symptomatic carotid 
artery stenosis in prevention of non-perioperative ipsilateral stroke. The summary estimate statistic is a Peto odds 
ratio (ﬁ xed-eﬀ ect model), the centre of the diamond is the point estimate, and the ends of the line are the 95% CI. 
The I-square statistic gives an indication of heterogeneity, where 0% suggests that it might not be important. The 
value of I-squared depends on the magnitude and direction of eﬀ ects and the strength of evidence for 
heterogeneity (p value from χ2 test).
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In conclusion, more patients in the endovascular group 
had a stroke during follow-up than did patients in the 
surgical group, but the rate of ipsilateral non-perioperative 
stroke was low in both groups and none of the diﬀ erences 
in the stroke outcome measures reached statistical 
diﬀ erence. However, the study was underpowered and 
the conﬁ dence intervals are wide. The low rate of 
long-term stroke longer than 30 days after endovascular 
treatment supports the use of endovascular treatment to 
prevent long-term stroke in patients in whom carotid 
endarterectomy is contraindicated or who prefer to risk 
the possibly greater hazard of endovascular treatment 
over surgery. However, the results do not support the use 
of endovascular treatment in preference to surgery in 
patients who are suitable for both treatments; there were 
also more minor strokes within 30 days of endovascular 
treatment and a greater incidence of restenosis. These 
results emphasise the need for further data from the 
short-term and long-term comparison of endovascular 
treatment with endarterectomy in trials that are on going, 
including the International Carotid Stenting Study 
(ICSS) and the Carotid Revascularisation Endarterectomy 
versus Stent Trial (CREST).16–18 There is a strong 
suggestion from the subgroup analysis of SPACE and 
EVA-3S, which is supported by the subgroup analysis in 
CAVATAS, that the small additional hazard of 
endovascular treatment applies only to older patients and 
that the two treatments might be equivalent in young 
patients. The Carotid Stenting Trialists Collaboration has 
recently been established to analyse the pooled data from 
the recent large trials, to establish more clearly in which 
subgroups endarterectomy is the treatment of choice and 
in which subgroups endovascular treatment has 
equivalent risks. Stenting avoids some of the minor 
complications of carotid endarterectomy and therefore 
would be the treatment of choice in any subgroups in 
which it could be shown to have equivalent safety and 
long-term outcome.
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